Date: May 16, 2012 Source: (
click here to go to the source)
inShare
San Francisco-based Nurix, a stealth mode startup which looks to be headed by Timothy Kutzkey, a venture capitalist at The Column Group, has raised $3.1M in a funding, according to a regulatory filing by the firm. Details on what the company is working on, and the financing, have not been announced. Jobs listings for the firm indicate that it is focused on the discovery and development of small molecule inhibitors of ubiquitin ligases to treat a broad range of proliferative and degenerative diseases. Those same listings say the company has the backing of The Column Group and Third Rock Ventures.
